呼出挥发性有机化合物作为哮喘用药标志物
该研究基于U-BIOPRED队列的78例重症哮喘患者,采用气相色谱-飞行时间质谱检测呼出挥发性有机化合物(VOCs),并与尿液沙丁胺醇和口服糖皮质激素水平进行关联分析。基线AUC对沙丁胺醇为82.1%(95%CI 70.4-93.9%),对口服糖皮质激素为78.8%(95%CI 65.8-91.8%),结果可重复并验证。呼出VOCs与尿药浓度显著相关(p<0.01),提示呼吸组学有望用于治疗药物监测。
要点
- 呼出VOCs可区分哮喘患者是否使用沙丁胺醇或口服糖皮质激素。
- 基线AUC:沙丁胺醇82.1%,口服糖皮质激素78.8%。
- 呼出VOCs与尿液药物浓度显著相关(p<0.01)。
核心结论
- 呼出VOCs与尿液检测到的沙丁胺醇和口服糖皮质激素相关联。
- 呼吸组学值得进一步开发为治疗药物监测的即时检测工具。
研究设计与样本
- 研究纳入U-BIOPRED队列的78例重症哮喘患者(基线n=48,重复n=30,验证n=30)。
- 采用气相色谱-飞行时间质谱检测呼出VOCs,液相色谱-高分辨质谱检测尿液沙丁胺醇和口服糖皮质激素。
- 样本在基线和随访12-18个月后采集,统计采用单变量和多变量建模并计算AUC。
主要发现
- 基线AUC对沙丁胺醇为82.1%(95%CI 70.4-93.9%)。
- 基线AUC对口服糖皮质激素为78.8%(95%CI 65.8-91.8%)。
- 结果可通过纵向重复和独立验证充分重现。
- 合格呼出VOCs与尿液沙丁胺醇和泼尼松浓度呈显著相关(p<0.01)。
临床怎么用
- 呼出VOCs检测有望作为无创手段监测哮喘患者用药依从性和药物暴露。
- 目前尚处于研究阶段,需进一步开发为临床即时检测工具。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Asthma is a heterogeneous condition, characterised by chronic inflammation of the airways, typically managed with inhaled bronchodilators and corticosteroids. In the case of uncontrolled asthma, oral corticosteroids (OCSs) are often prescribed. Good adherence and inhalation technique are associated with improved outcomes; however, it is difficult to monitor appropriate drug intake and effectiveness in individual patients. Exhaled breath contains thousands of volatile organic compounds (VOCs) that reflect changes in the body's chemistry and may be useful for monitoring drug pharmacokinetics/pharmacodynamics. We aimed to investigate the association of exhaled VOCs in severe asthma patients from the U-BIOPRED cohort (by gas chromatography coupled with time-of-flight mass spectrometry) with urinary levels of salbutamol and OCSs (by liquid chromatography coupled with high-resolution mass spectrometry). METHODS: Samples were collected at baseline and after 12-18 months of follow-up. Statistical analysis was based on univariate and multivariate modelling, followed by area under the receiver operating characteristic curve (AUC) calculation. Results were verified through longitudinal replication and independent validation. RESULTS: Data were available for 78 patients (baseline n=48, replication n=30 and validation n=30). Baseline AUC values were 82.1% (95% CI 70.4-93.9%) for salbutamol and 78.8% (95% CI 65.8-91.8%) for OCS. These outcomes could be adequately replicated and validated. Additional regression analysis between qualified exhaled VOCs and urinary concentrations of salbutamol and prednisone showed statistically significant correlations (p<0.01). CONCLUSION: We have linked exhaled VOCs to urinary detection of salbutamol and OCSs. This merits further development of breathomics into a point-of-care tool for therapeutic drug monitoring.
引用
- Brinkman P, Ahmed WM, Gómez C, et al. Exhaled volatile organic compounds as markers for medication use in asthma. Eur Respir J. 2020. PMID: 31515400. doi:10.1183/13993003.00544-2019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。